Dr. Black Discusses the Impact of Durvalumab in Bladder Cancer

Peter Black, MD
Published: Friday, Jul 21, 2017



Peter Black, MD, senior research scientist, Vancouver Prostate Center, associate professor, Department of Urologic Sciences, University of British Columbia, discusses the impact of durvalumab (Imfinzi) in bladder cancer.

Durvalumab is approved for use in patients with locally advanced or metastatic bladder cancer who have disease progression during or following platinum-containing chemotherapy, or who have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.

In addition to treating patients, durvalumab has brought a lot of industry and research interest to bladder cancer, says Black.


Peter Black, MD, senior research scientist, Vancouver Prostate Center, associate professor, Department of Urologic Sciences, University of British Columbia, discusses the impact of durvalumab (Imfinzi) in bladder cancer.

Durvalumab is approved for use in patients with locally advanced or metastatic bladder cancer who have disease progression during or following platinum-containing chemotherapy, or who have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.

In addition to treating patients, durvalumab has brought a lot of industry and research interest to bladder cancer, says Black.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x